Telaprevir Phase IIb Data Continues To Support 24-Week Dosing For Hepatitis C, Vertex Says
This article was originally published in The Pink Sheet Daily
Executive Summary
PROVE-2 data show 65 percent sustained viral response in treatment naive patients, Vertex reports.
You may also be interested in...
Schering-Plough’s Low AE Profile For Boceprevir Phase II Could Be Advantage Over Vertex’s Telaprevir In HCV Race
Vertex tells “The Pink Sheet” DAILY that VX-950 has more robust data, including new numbers scheduled for release at a major medical meeting next month.
Vertex Second Phase II Study Supports Telaprevir 24-Week Regimen
Adverse events associated with the hep C treatment are “troublesome,” not “troubling,” Vertex CEO Boger says.
Interim Phase II Telaprevir Data Point To Possible Shortened Hep C Treatment Course
Vertex hopes to base Phase III trial design on 12-week dosing with telaprevir plus standard of care followed by standard of care for 12 weeks.